Procarta raises €1.5 million to develop a new class of antibiotics to combat antimicrobial resistance

UK-based biotech startup Procarta Biosystems is developing novel therapies to combat AMR. The startup has raised €1.5 million in new funding from the Novo Holdings REPAIR Impact Fund, which will be used to develop a pipeline of an entirely new class of antibiotic precision medicines from Procarta’s proprietary oligonucleotide-based antimicrobial platform.